Christopher Stokoe

Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA

M.C. Liu, Geoffrey R. Oxnard, Eric A. Klein et al. · Annals of Oncology · 2020 · 1.4K citations · Full text

NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+

Louis Fehrenbacher, Reena S. Cecchini, Charles E. Geyer et al. · Journal of Clinical Oncology · 2019 · 406 citations · Full text

Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study

Stephen E. Jones, Rufus Collea, Devchand Paul et al. · The Lancet Oncology · 2013 · 134 citations

Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine

Joyce O’Shaughnessy, Hartmut Koeppen, Yuanyuan Xiao et al. · Clinical Cancer Research · 2015 · 58 citations

Abstract GS1-02: NSABP B-47 (NRG oncology): Phase III randomized trial comparing adjuvant chemotherapy with adriamycin (A) and cyclophosphamide (C) → weekly paclitaxel (WP), or docetaxel (T) and C with or without a year of trastuzumab (H) in women with node-positive or high-risk node-negative invasive breast cancer (IBC) expressing HER2 staining intensity of IHC 1+ or 2+ with negative FISH (HER2-Low IBC)

L. Fehrenbacher, RS Cecchini, CE Geyer et al. · Cancer Research · 2018 · 50 citations

Breast Oncology, Cancer Management, Adjuvant Chemotherapy +17